Literature DB >> 22484770

Cochlea radiation dose correlates with hearing loss after stereotactic radiosurgery of vestibular schwannoma.

Melanie G Hayden Gephart1, Ake Hansasuta, Raymond R Balise, Clara Choi, Gordon T Sakamoto, Andrew S Venteicher, Scott G Soltys, Iris C Gibbs, Griffith R Harsh, John R Adler, Steven D Chang.   

Abstract

OBJECTIVE: For multisession radiosurgery, no published data relate the volume and dose of cochlear irradiation to quantified risk of hearing loss. We conducted a retrospective, dosimetric study to evaluate the relationship between hearing loss after stereotactic radiosurgery (SRS) and the dose-volume of irradiated cochlea.
METHODS: Cochlear dose data were retrospectively collected on consecutive patients who underwent SRS (18 Gy in 3 sessions) for vestibular schwannoma between 1999 and 2005 at Stanford University Hospital. Inclusion criteria included Gardner-Robertson (GR) grade I or II hearing prior to radiosurgical treatment, complete audiograms, and magnetic resonance imaging (MRI) follow-up. A cochlea dose-volume histogram was generated for each of the 94 patients who qualified for this study.
RESULTS: GR grade I-II hearing posttreatment was maintained in 74% of patients (70/94). Median time to last follow-up audiogram was 2.4 years (range 0.4-8.9) and to last MRI was 3.6 years (range 0.5-9.4). Each higher level of cochlear irradiation was associated with increased risk of hearing loss. Larger cochlear volume was associated with lower risk of hearing loss. Controlling for differences in cochlear volume among subjects, each additional mm(3) of cochlea receiving 10 to 16 Gy (single session equivalent doses of 6.6-10.1 Gy3) significantly increased the odds of hearing loss by approximately 5%.
CONCLUSIONS: Larger cochlear volume is associated with lower risk of hearing loss following trisession SRS for vestibular schwannoma. Controlling for this phenomenon, higher radiation dose and larger irradiated cochlear volume are significantly associated with higher risk of hearing loss. This study confirms and quantifies the risk of hearing loss following trisession SRS for vestibular schwannoma.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cochlea; GR; Gardner–Robertson classification; Hearing preservation; MRI; Magnetic resonance imaging; Radiation; SRS; Stereotactic radiosurgery; Vestibular schwannoma

Mesh:

Year:  2012        PMID: 22484770      PMCID: PMC6419735          DOI: 10.1016/j.wneu.2012.04.001

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  14 in total

Review 1.  [Radiosurgery and fractionated stereotactic radiotherapy of vestibular schwannoma].

Authors:  K Hamm; H-U Herold; G Surber; S Rosahl
Journal:  HNO       Date:  2017-05       Impact factor: 1.284

2.  Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation.

Authors:  Zhiping Chen; Keiichi Takehana; Takashi Mizowaki; Megumi Uto; Kengo Ogura; Katsuyuki Sakanaka; Yoshiki Arakawa; Yohei Mineharu; Yuki Miyabe; Nobutaka Mukumoto; Susumu Miyamoto; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2018-03-19       Impact factor: 3.402

Review 3.  The emerging role of hearing loss rehabilitation in patients with vestibular schwannoma treated with Gamma Knife radiosurgery: literature review.

Authors:  Carlotta Morselli; N Boari; M Artico; M Bailo; L O Piccioni; I Giallini; M de Vincentiis; P Mortini; P Mancini
Journal:  Neurosurg Rev       Date:  2020-02-06       Impact factor: 3.042

4.  Systematic Review of Normal Tissue Complication Models Relevant to Standard Fractionation Radiation Therapy of the Head and Neck Region Published After the QUANTEC Reports.

Authors:  N Patrik Brodin; Rafi Kabarriti; Madhur K Garg; Chandan Guha; Wolfgang A Tomé
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-29       Impact factor: 7.038

5.  Health Care Utilization in Patients Undergoing Repeat Stereotactic Radiosurgery for Vestibular Schwannoma with 5-Year Follow-up: A National Database Analysis.

Authors:  Nicholas Dietz; Mayur Sharma; Beatrice Ugiliweneza; Dengzhi Wang; Maxwell Boakye; Brian Williams; Norberto Andaluz
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-10

6.  Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial.

Authors:  Anurag Saraf; Luke R G Pike; Kevin H Franck; Nora K Horick; Beow Y Yeap; Barbara C Fullerton; Irene S Wang; Mohamed E Abazeed; Michael J McKenna; William A Mehan; Scott R Plotkin; Jay S Loeffler; Helen A Shih
Journal:  Neurosurgery       Date:  2022-05-01       Impact factor: 5.315

7.  Long-Term Hearing Outcomes Following Stereotactic Radiosurgery in Vestibular Schwannoma Patients-A Retrospective Cohort Study.

Authors:  Peter L Santa Maria; Yangyang Shi; Richard K Gurgel; C Eduardo Corrales; Scott G Soltys; Chloe Santa Maria; Kevin Murray; Steven D Chang; Nikolas H Blevins; Iris C Gibbs; Robert K Jackler
Journal:  Neurosurgery       Date:  2019-10-01       Impact factor: 4.654

8.  Systematic Review of Hearing Preservation After Radiotherapy for Vestibular Schwannoma.

Authors:  Adam R Coughlin; Tyler J Willman; Samuel P Gubbels
Journal:  Otol Neurotol       Date:  2018-03       Impact factor: 2.311

9.  Clinical evaluation of CyberKnife in the treatment of vestibular schwannomas.

Authors:  Jo-Ting Tsai; Jia-Wei Lin; Chien-Min Lin; Yuan-Hao Chen; Hsin-I Ma; Yee-Min Jen; Yi-Hsun Chen; Da-Tong Ju
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

10.  Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy.

Authors:  Mira A Patel; Ariel E Marciscano; Chen Hu; Ignacio Jusué-Torres; Rupen Garg; Arif Rashid; Howard W Francis; Michael Lim; Kristin J Redmond; Daniele Rigamonti; Lawrence R Kleinberg
Journal:  Front Oncol       Date:  2017-09-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.